During the last decades, extended characterizations were performed of human fullterm cord blood (hTCB) cells, but little information is available on human early preterm cord blood (hEPCB) hematopoietic stem cells (HSCs). In our study, we analyzed by flow cytometry 19 hEPCB and 17 hTCB samples. First, we observed that the percentage of CD34 Pos CD45 Dim cells was higher in hEPCB compared with hTCB and that it decreased during 16th-20th week of pregnancy. Within the CD34 Pos CD45 Dim population, we examined the expression of CD29, CD31, CD38, CD90, CD117, CD133, CD135, CD200, CD243, and CD338. We found that CD135 intensity and CD243 Pos cells percentage were lower in hEPCB compared with hTCB. As to CD38, we observed that hEPCB samples were richer in undifferentiated CD34Pos CD45 Dim CD38 Neg HSCs compared with hTCB counterparts. We also compared the expression of the abovementioned molecules in undifferentiated and committed HSCs residing in hEPCB and hTCB.
CD133Pos cells compared with hTCB samples. Finally, analyzing monocytes and lymphocytes within the two samples, we observed that T-cell percentages were higher in hTCB, whereas B-cell percentages were higher in hEPCB. We, therefore, studied the B-cell lineage maturation and found a higher percent of pro-B and pre-B cells in hEPCB compared with hTCB samples. Taken together, these results evidence the hematopoietic peculiarity of hEPCB, potentially useful for highlighting early steps of human hematolymphopoiesis as well as for developing novel strategies of stem cell-based therapy. ' 2010 International Society for Advancement of Cytometry
Key termsfetal cord blood; CD34; hematopoietic stem cells; flow cytometry; B-lymphocytes; early preterm cord blood DURING the past decade, human full-term cord blood (HTCB) has been considered to be an attractive hematopoietic stem cells (HSC) source not only for transplantation purposes, but also for basic research investigators studying useful marker to identify immature stages of HSC differentiation (1-3). Compared with mobilized peripheral blood stem cells and marrow HSCs, CB-HSCs are essentially characterized by a series of advantages such as less-stringent HLA-matching requirements between donors and recipients, absence of ethical concerns as well as risks for the mother and the infant, low Epstein Barr virus and cytomegalovirus contaminations, immediate availability of frozen units, and maintenance of ethnic balance by targeted collection programs (1).